Vaccines and drugs in the pipeline for RSV

(Reuters) There are no approved vaccines and only one drug in the United States for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Sanofi and AstraZeneca drug nirsevimab recently became the second to get Europe’s approval to prevent RSV infections in infants, after Swedish drugmaker Orphan Biovitrum’s Synagis. Nirsevimab does not have U.S. approval yet.